Cargando…
A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
Autores principales: | Millns, Helen, Bergemann, Rito, Ackermann, Elizabeth, Monia, Brett, Lukas, Mary Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641994/ http://dx.doi.org/10.1186/1750-1172-10-S1-P8 |
Ejemplares similares
-
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015) -
The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences
por: Bergemann, Rito, et al.
Publicado: (2015) -
Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017) -
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2021) -
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
por: Niemietz, Christoph, et al.
Publicado: (2015)